DOMANICO RONALD JAMES
Known title: EVP, Chief Financial OfficerCIK: 0001239016
Associated companies
Transaction History
| BCO | ▼ Sell | Tax Withholding | 44,342 | $2.5M | 7/12/2022 | View on chart |
| BCO | ▲ Buy | Option Exercise | 84,985 | $2.5M | 7/12/2022 | View on chart |
| BCO | ▲ Buy | Grant | 7,480 | $0 | 3/1/2022 | View on chart |
| BCO | ▼ Sell | Tax Withholding | 166 | $12K | 2/24/2022 | View on chart |
| BCO | ▼ Sell | Tax Withholding | 405 | $28K | 2/21/2022 | View on chart |
| BCO | ▼ Sell | Tax Withholding | 608 | $42K | 2/20/2022 | View on chart |
| BCO | ▼ Sell | Tax Withholding | 1,206 | $84K | 2/17/2022 | View on chart |
| BCO | ▲ Buy | Grant | 3,828 | $0 | 2/17/2022 | View on chart |
| BCO | ▲ Buy | Option Exercise | 96 | $0 | 1/1/2022 | View on chart |
| BCO | ▼ Sell | Tax Withholding | 22 | $1K | 1/1/2022 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 9, 2026
Brink's Gets CMA Approval for NCR Atleos Deal Remedy
Brink's received acceptance in principle from the UK's CMA regarding a proposed remedy for its pending acquisition of NCR Atleos. The company also reported Q2 2026 results and confirmed that a potential sale of UK assets will not impact expected $200M in annual synergies. This regulatory progress is a key step in finalizing the transaction.
Brink's Gets CMA Approval for NCR Atleos Deal Remedy. Brink's received acceptance in principle from the UK's CMA regarding a proposed remedy for its pending acquisition of NCR Atleos. The company also reported Q2 2026 results and confirmed that a potential sale of UK assets will not impact expected $200M in annual synergies. This regulatory progress is a key step in finalizing the transaction.